AstraZeneca has announced a new Phase III study to determine if adding Farxiga ( dapagliflozin ) to insulin is a...
AstraZeneca announced that the FDA has issued a complete response letter regarding the supplemental New Drug Application for Farxiga (dapagliflozin)...
AstraZeneca has announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the...
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin) which showed that...
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF.
Detailed results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (EF), compared to placebo.
AstraZeneca announced the FDA has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to...
AstraZeneca announced that the FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in...
Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease (ckd) stages 2-4 and elevated urinary albumin excretion. the results were consistent in patients both with and without type-2 diabetes (t2d).